Key clinical point: Combination therapy (mifepristone followed by misoprostol) was significantly more cost effective than misoprostol alone for managing miscarriage.

Major finding: Cost differences in favor of combination therapy over monotherapy ranged from 6.3% to 19.5% among patients across several income categories.

Study details: The data come from a decision tree analysis using Monte Carlo simulations to compare combination therapy with mifepristone and misoprostol with misoprostol alone.

Disclosures: The study received no outside funding. The researchers had no financial conflicts to disclose.